Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 09:39 AM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Penny Stock Picks » Strong Buy: IGXT (Mcap $32 M) Submits NDA in March + 3x NDA filings in 1H13



Reply
 
Thread Tools Search this Thread
Old 04-01-2013, 06:13 AM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Default IGXT (Mcap $32 M) Submits NDA in March + 3x NDA filings in 1H13

This is a real once in a lifetime opportunity ..GLTA

Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by in 2013 because of its very low burn-rate of just $1.2 Mil a year !

IGXT Submits next NDA to the FDA for an Anti-Migraine Versafilm last Week and another 3x More NDA/ANDA filings expected in 1H 2013. This Goldmine has 9x Drugs in their Mega Pipeline which will be all on the Market within next 2-3 years .


IGXT has NO DEBT and current Market cap of just $32 M is really a BIG BIG BARGAIN .

My Target is $8-12 within 2 Years .GLTA


Intelgenx (IGXT)

Market Cap : $32 M
Cash: $3.5 M
Burn-Rate : $1.2 M a year

Price : $0.63

Shares Out : 50 M ( 27 M shares are held by Insiders & Institutions)


"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.

March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.



HUGE Prodcut Pipeline
http://wsw.com/webcast/roth27/igxt/2__Slide6.JPG


Upcoming Milestones
http://wsw.com/webcast/roth27/igxt/2__Slide19.JPG


New Presentation March 2013
http://de.slideshare.net/ViralNetwor...sentation-2012


Big Buying by Institutions
http://finance.yahoo.com/q/it?s=IGXT...r+Transactions


Analyst Coverage:

IGXT gets 18 month $3.00 Price Target from AEGIS CAPITAL CORP on October 5th, 2012
http://image.slidesharecdn.com/aegis...phpapp01/95/sl
ide-1-1024.jpg?1349900345

Cleland shares the names of a handful of small companies that could return tenfold or greater multiples to investors.
http://www.thelifesciencesreport.com/pub/na/14076

TLSR: What types of healthcare companies are you looking for? Do you lean toward specialty pharma, where you can monetize more quickly? What are your preferences?

I have at least two investments in this area—is in the FDA's 505(b)(2) pathway, also known as the rapid approval route. This pathway can be used by companies taking an existing drug with hundreds of millions or several billion dollars in sales and porting that drug onto a different delivery technology. Biovail Corp. (now part of Valeant Pharmaceuticals International Inc. [VRX:NYSE]) followed this pathway when it made Wellbutrin XL, a one-a-day version of Wellbutrin (bupropion hydrochloride). IntelGenx (IGX:TSX.V; IGXT:OTCQX) is my poster child in this area, with eight drugs in various stages of the 505(b)(2) approval process, and one 505(b)(2) drug that will be commercially launched this fall, having received FDA approval in November 2011.

TLSR: What's the next company you'd like to talk about?

HC: IntelGenx is the company through which I learned about the 505(b)(2) pathway, and why that pathway is so attractive to me. It's a drug delivery company that takes existing, commercialized drugs and ports them onto different delivery modalities, making them better from a patient compliance perspective or from a time-to-onset-of-action perspective. The existing drugs the company is working with have commercial revenues in the hundreds of millions to several billion-dollar range.

IntelGenx is about to launch its antidepressant drug, having received FDA approval in November 2011, and has a pipeline of eight drugs being developed via the 505(b)(2) pathway. The company is a table-pounder, simply on the basis that it has an approved drug and a market cap of only $30M. It is truly one of the most dramatic valuation disconnects that I am aware of. Full disclosure: Funds that I manage control about 12% of the company.

A migraine drug called rizatriptan is a good example of one of IntelGenx's pipeline drug applications. The time to onset of action of a migraine medication is very important. If the medication is delivered in time, it can cut a migraine off at its knees and save the patient from an ugly 12–36 hours. On the other hand, if a patient pops a pill and it takes 45 minutes to kick in, a migraine may get the foothold it needs to overwhelm the medication.

IntelGenx is moving rizatriptan onto a thin film strip. The time to onset of action for a drug delivered via sublingual strip is much faster than for the pill form. Annual sales of prescription migraine drugs on a global basis are probably more than $5B; annual sales of rizatriptan were over $600M in 2011. If IntelGenx can introduce a better form of the drug, cutting the time to onset of action in half or more—or even if the film cuts it by a third—doctors and patients will be very attracted. IntelGenx's drug could gain market share quickly in the migraine medication area. In another example, the company is moving an erectile dysfunction drug onto a strip. You can imagine reasons you may want quicker onset of action with that.

The bottom line from an investor perspective is that, as of the close on Aug. 3, 2012, the stock is lower than it was before the company's antidepressant received FDA approval on Nov. 11, 2011; lower than it was before its December 2011 codevelopment and commercialization deal with Par Pharmaceutical Inc.; and lower than it was before the announcement of a commercialization partner for its antidepressant. I would argue that at $0.80 or lower, the only thing an investor is paying for is the antidepressant, meaning that you are getting the entire thin-film delivery platform and eight pipeline drugs for free.

I suggest that investors check out the analyst report published two weeks ago by Ram Selvaraju of Aegis Capital Corp., initiating coverage on IntelGenx with a $2.50/share, 18-month target. Ram is known as one of the few analysts willing to pick up coverage on sub-$50M market cap companies—as long as he thinks that he can make investors significant returns. One of his more notable sub-$50M initiations was Amarin, back in 2009, when it had a market cap of about $40M.
Biohero is online now   Rate this post Yes | No Reply With Quote
Old 04-08-2013, 07:10 AM   Nav to Top  #2
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Intelgenx has a unique Potency drug which works much faster than all ED drugs on the Market like Viagra ,Cialis and Levitra . IGXT´s Potency Drug alone is worth more than $2++ per Share .

Partnership is Imminent and NDA filing for this Potency drug is planned for 1H 2013 .

Tadalafil film – indicated for Erectile Dysfunction

IntelGenx’ tadalafil film is a new product opportunity formulated using VersaFilm™, IntelGenx’ proprietary thin film technology. Tadalafil is one of the three major PDE5 inhibitors in the erectile dysfunction market. Compared with the competitors, tadalafil shows longer duration of action and less food effect. IntelGenx’ tadalafil film offers an improved discrete dosage form that does not require water intake. IntelGenx tadalafil film formulations have been tested in various clinical trials to improve the pharmacokinetics and optimize the formulation. The latest formulation is planned to be tested in a pilot study in Q4 2012. IntelGenx is currently looking for a partnership or alliance opportunity to complete development and commercialize the tadalafil film.

---

Wafer Viagra For Instant Results

One of the big challenges for erectile dysfunction medicine manufacturers is to quicken the time between the application of the medicine and its response. Men want instant results when they take Viagra, Cialis or Levitra and complain that having to wait as much as thirty minutes before the active ingredient is effective can burst the bubble of spontaneity and passion which are often essential requirements of good sex.

Well a solution could be at hand following research done by a Canadian research company called IntelGenx who have developed wafers [like the common breath freshness ones] that are designed to melt on your tongue which they say will get the medicine into your bloodstream around 30% faster than by using conventional tablets.

IntelGenx say that because the mouth is lined with tiny blood vessels applying the wafer Viagra here can give a very fast application of the drug directly into the bloodstream.

Sometimes men complain that if they have eaten a large meal it can take an even longer time for the Viagra, Cialis and Levitra to take effect. If on the other hand they made use of erectile dysfunction medication in a wafer form applied directly to the mouth and therefore bypassing their digestive system this problem would disappear.

Using a wafer type of Viagra would also mean that you wouldn't have to go and get a glass of water in the middle of a passionate encounter in order to swallow your pill. Wafer Viagra would be a much more discreet application of impotence medication .
Biohero is online now   Rate this post Yes | No Reply With Quote
Old 04-17-2013, 08:57 AM   Nav to Top  #3
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

IntelGenx (IGXT) receives Analyst coverage from AEGIS - Buy Rating with Price Target !!!

Initiating Coverage. We are initiating coverage on IntelGenx Technologies Corp., an emerging specialty pharmaceuticals company, with a Buy rating and an 18-month price target of $2.50 per share. In our view, IntelGenx is an extremely undervalued company with a highly risk-mitigated product candidate pipeline, three valuable technology platforms, and a very capital-efficient business model. The firm has demonstrated the ability to develop drug candidates rapidly using the so-called 505(b)(2) regulatory pathway and has even managed to get one of its agents approved by the FDA in the U.S. without any help from a partner, which is unheard-of for firms of this size.

Multiple Value Drivers Ahead. We believe that, with a market cap of under $32 mm and potential to achieve cash flow positive status in 2013, this company should be the focus of investor attention. Since the firm utilizes the 505(b)(2) pathway, all of its drug candidates are based on well-known agents that have already been approved in some other form. This mitigates risk and also allows IntelGenx to move pipeline candidates from concept into the clinic at an unprecedented rate.

Unwarranted Valuation Discrepancy. We note that IntelGenx's current enterprise value is lower than the aggregate value of the milestone payments due to the firm on future sales of Forfivo?. Further, we would point out that even though IntelGenx closed 1Q 2013 with only $3.5mm in cash, the firm uses so little cash to fund operations that we do not project any near-term financing need.
Biohero is online now   Rate this post Yes | No Reply With Quote
Old 04-24-2013, 08:03 AM   Nav to Top  #4
stockmountie
Senior Trader
 
stockmountie's Avatar
 
Join Date: Oct 2011
Location: Canada
Posts: 485
Favorites: SSH.V CZH.V EDW.V
Rep Power: 118
Reputation: 66
stockmountie will become famous soon enough
Default IntelGenx (IGXT) Secures Leadership Succession

IntelGenx (IGXT) Secures Leadership Succession


SAINT LAURENT, Quebec, April 24, 2013 (GLOBE NEWSWIRE) -- Horst Zerbe, President and CEO of IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company") today announced that Rajiv Khosla RPh, PhD, MBA has been appointed Chief Operating Officer and Chief Scientific Officer of the Company, effective immediately. Dr. Khosla has been a member of the Company's board of directors for the past two years and, in accordance with the employment agreement, has now relinquished his board position.

"I am elated that Dr. Khosla has agreed to bring his outstanding leadership abilities and vision to IntelGenx on a full-time basis," Dr. Zerbe said, adding that the appointment is key to the Company's strategic plan for smooth succession, continuity and growth.

"We have secured the right leadership for the future," Dr. Zerbe said. "Rajiv has a record of success in business development and in leading growth in our sector. Those are essential attributes as IntelGenx moves forward."

Dr. Zerbe also noted that Dr. Khosla has deep knowledge in drug delivery systems. He is the first COO at IntelGenx. The succession plan will see Dr. Khosla become CEO and President of IntelGenx on January 1, 2014 and for Dr. Zerbe, who built the Company from the ground up, to remain as Chairman of the board of directors and continue to provide expertise in research and development, and manufacturing.

Since the beginning of this year, Dr. Khosla has been a consulting member of the IntelGenx management team, assisting with strategic operations, business development activities and advising on current and future pharmaceutical project development.

IntelGenx, a Canadian company, develops drug delivery systems that solve challenges encountered in oral drug delivery, with technologies that improve the performance of a wide variety of pharmaceutical compounds. IntelGenx has developed capacities to tailor drug release profiles and target specific absorption sites to unlock the full therapeutic potential of a drug. It recently submitted a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm™ technology

Dr. Khosla has remarkable experience and credentials including, among other senior positions, five years as Vice President of Business Development at Biovail Corporation, a Canadian pharmaceutical company operating internationally. Whilst there, Dr. Khosla successfully led the transaction process for more than 75 deal opportunities in a variety of therapeutic areas.

He holds a Ph.D. in pharmaceutical science, with a thesis on Oral Drug Delivery Technology; an Executive MBA from the Henley Business School in England, a Bachelor of Pharmacy (Honours) from the University of Nottingham, England and is a registered pharmacist in the UK.

About IntelGenx:

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, idiopathic pulmonary fibrosis, allergies and pain management. More information is available about the company at www.intelgenx.com.
stockmountie is offline   Rate this post Yes | No Reply With Quote
Old 04-24-2013, 02:06 PM   Nav to Top  #5
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Still time to get in very cheap ...

Apr 24 10:45 AM

http://seekingalpha.com/user/192072/instablog

It has been a while, but IntelGenx has finally decided to add an experienced senior executive with significant experience in drug formulation and business development. Dr. Rajiv Khosla has been appointed COO and CSO for the company and will become the new CEO at the beginning of 2014. Dr. Khosla will continue the work that he has been doing since being appointed to the management team as a consultant at the beginning of 2013.

Looking back at his track record, I think Dr. Khosla is well-equipped for the upcoming commercial phase and should be more aggressive in licensing/partnering activities. Dr. Khosla has over 30 years of experience for five different specialty pharmaceutical companies, including a five year stint at Biovail where he was involved in more than 75 deals. I believe his experience will be valuable in deal making which is where IntelGenx need a little more muscle given the number of new projects maturing and in need of commercial partners.

With their first FDA approved product, Forfivo XL™, an anti-depressant, launched late in 2012, I am becoming more optimistic about the company becoming profitable in the coming quarters. With another 10 drugs in development and a high probability of regulatory approval, I expect the majority of these drugs to be on the market by 2016. I expect the major risk is not about clinical development and approvability but rather on the commercial timing. Given that all of these drugs are second or third generation drugs, the commercial viability and success depends on the market timing and its reimbursement. If you saw the movie "A Good Year (2006)", Russell Crowe, as a young kid, was asked by his uncle what is the most important thing in life and the uncle said "TIMING". With my short thirty years of experience in the sector both as an analyst and in business development, I can vouch for that also.

Valuation

For healthcare companies, the analysis is usually quite complex because many of them have little or no revenues. For emerging technology companies like IntelGenx, the valuation is based on the drug assets in development and the people. The people have been successful at developing 2 drugs so far and another 10 using three different formulations which offer equivalent or better safety profiles for patients and, in some cases, are cheaper than the competition. If you assume an 80% success rate for the drugs currently being developed and an expected average of $50-$100m in end-user sales, with 20% royalties for IGXT, this would mean an EPS of $2.50-$5.00; excluding taxes. Not bad for a company with around 10 people and no debt. Another nice feature for IntelGenx has been is low burn rate which has been below most companies, especially those located in the US, built around ex-Pharma people and salaries. The company has plenty of cash, no lawsuits, and multiple patents to cover their work.

Maybe the approach is too simplistic; however let's look at the most promising drug in the pipeline which is the anti-migraine drug. This is a $2bn US market with current treatments which I see as basically similar. Then you have IntelGenx with a novel oral strip formulation of the very popular Maxalt (marketed by Merck and now off patent) which sold more than $600m last year. What people need to focus is that when a new formulation comes in the market; it may also expand and captures market share from pretty similar drugs if it works. Patients who have migraine issues need faster onset of action rather than better pricing and doctors are looking for drugs that are safe, fast and efficacious. People don't die from migraine but if you ever had it, you don't care how much it costs, as long as it works. I believe this anti-migraine product could be a $200-300m product at peak revenues and the timing is perfect given that I don't expect any new drugs to hit the market in the next 2-3 years. This is a 2014 event for IntelGenx and it could be important for the company history.
Biohero is online now   Rate this post Yes | No Reply With Quote
Old 05-10-2013, 01:45 PM   Nav to Top  #6
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

NDA acceptance coming within 2 weeks ... A lot of good news is on the way all you need here is patience .

New Presentation
http://intelgenx.com/investors/presentations.html
Biohero is online now   Rate this post Yes | No Reply With Quote
Old 05-15-2013, 08:18 AM   Nav to Top  #7
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

More good News coming out yesterday ..

The Erectile Dysfunction drug was successfully in final Study now the next steps are Partnership and NDA filing which coming within 4 months . NDA acceptance for Anti-Migraine drug coming within 2 weeks .

Another 2 ANDA filings includes the big Par Pharma drug coming before year end . Market Cap of $30 Million is really a Big joke .

http://finance.yahoo.com/news/intelg...100500949.html

Corporate Development Update

Anti-migraine VersaFilm(TM) (rizatriptan)

In March 2013 we announced that, together with our co-development partner RedHill Biopharma Ltd. ("RedHill"), we submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for our anti-migraine oral film product, a novel oral thin-film formulation based on our proprietary VersaFilm(TM) technology containing rizatriptan, the active drug in Merck & Co. ("Merck's") Maxalt-MLT(R) orally disintegrating tablets. According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.

Erectile Dysfunction VersaFilm(TM) (tadalafil)

In February 2013 we successfully completed a pilot bioequivalence study on our erectile dysfunction VersaFilm(TM) product. In a previous study, we had already demonstrated that we are able to formulate a bioequivalent product. In the recently completed study, we showed that we were additionally able to develop a faster formulation with a significantly shorter Tmax which will address the potential need for a faster tadalafil product. We are in active discussions for the licensing of this product.

Development and Commercialization Agreement with Par Pharmaceutical, Inc.

In December 2011 we announced the execution of a co-development and commercialization agreement with Par Pharmaceutical, Inc. ("Par") for a new product utilizing one of our proprietary oral drug delivery platform technologies. This program continues to make progress. For commercial reasons, and in order to protect both Par's and IntelGenx' competitive advantage, the agreement stipulates that all information pertaining to the product, together with financial terms of the agreement, are to remain confidential.

Antihypertensive VersaTab(TM) product

We recently completed a pilot bioequivalence study for our antihypertensive project, INT0001, a generic equivalent to a major cardiovascular product, using our proprietary VersaTab(TM) delivery technology. We continue to make progress with the project and, together with our strategic partner, Dava Pharmaceuticals Inc., are working diligently towards the filing of an ANDA with the FDA.
Biohero is online now   Rate this post Yes | No Reply With Quote
Old 05-22-2013, 08:30 AM   Nav to Top  #8
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

New Aegis Capital Update TGT $3 ...

https://aegis.bluematrix.com/sellsid...om&source=mail


IntelGenx: Looking Towards A Pivotal Year Ahead
May 20, 2013

Forfivo™ Traction Expected To Accelerate. We note that Forfivo™ has now been available in the U.S. for roughly six months, and that IntelGenx's partner Edgemont Pharmaceuticals appears to have dealt with most of the initial snags that impacted the launch of the drug. Accordingly, therefore, we anticipate meaningful acceleration in Forfivo™ prescription volumes in the coming months. While we do not expect the drug to become a massive seller, we note that even a relatively modest revenue base would likely have substantial impact on IntelGenx's bottom line, and should be sufficient to drive the company towards profitability. We note that IntelGenx continues to exhibit a cost-effective operational approach, burning roughly $2mm or less per year. We reiterate our Buy rating and 18-month price target of $3.00 per share on IGXT.

Rizatriptan 505(b)(2) Application Filed. In March 2013, IntelGenx reported that it had filed for approval of an oral film-based proprietary formulation of rizatriptan, a well-known anti-migraine drug belonging to the triptan class. Rizatriptan, which was originally developed and commercialized by Merck & Co. (MRK/NYSE, Not Rated) under the trade name Maxalt, had sales of $638mm in 2012. The patent protection on Maxalt has now expired. We believe that, even in the face of generic competition, it should be possible for IntelGenx's oral film formulation to eke out a solid niche in the migraine market, particularly as the company's delivery approach provides substantial advantages from an absorbability perspective.

Management Transition Announced. IntelGenx recently appointed Dr. Rajiv Khosla, a widely-respected industry veteran who previously spent several years at Biovail Corporation - now Valeant Pharmaceuticals International (VRX/NYSE, Buy) - as Chief Scientific Officer and Chief Operating Officer. Dr. Khosla is also slated to assume the post of CEO effective January 2014. Horst Zerbe, the company's founder and current CEO, is expected to stay on as Chairman of the Board of Directors and is slated to continue to provide expertise on formulation, drug manufacturing and R&D. From our perspective, the appointment of Dr. Khosla is a solid step forward for IntelGenx and should enable the firm to operate more aggressively from an out-licensing and partnership standpoint.

Additional Catalysts Expected Near-Term. We believe that 2013 is likely to be a watershed year for IntelGenx because this is the first time that the company is in position to reap rewards from a marketed product - Forfivo - which is in full ramp mode, while simultaneously filing other drug candidates for approval with the FDA. In our view, even one or two regulatory submissions should catch the eye of discerning investors, the majority of whom we continue to believe are unaware of the potential inherent in IntelGenx's diversified product candidate portfolio and capital-efficient business model.
Biohero is online now   Rate this post Yes | No Reply With Quote
Old 06-18-2013, 08:21 AM   Nav to Top  #9
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Great News out the NDA is accepted . I contacted the CEO via email last week and he confirmed again that we can expect more new Partnerships in this year .

IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product
http://finance.yahoo.com/news/intelg...100500641.html


Look at this Mega Pipeline and you can have this all for a very rdiciulous Market Cap of around $29 Million but not for long thats for sure .

Product Application Status of Development

INT0004/2006 Antidepressant -- US launch in 4Q 2012

INT0008/2007 Migraine -- Submit NDA in March 2013

INT0007/2006 Erectile Dysfunction -- NDA filing later in 2013

INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing later in 2013

INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA filing later in 2013

INT0020/2010 Insomnia -- in Pivotal Study

INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study

INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study

INT0030/2011 Animal health -- in Pivotal Study

INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study
Biohero is online now   Rate this post Yes | No Reply With Quote
Old 06-27-2013, 01:54 PM   Nav to Top  #10
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Small-Cap Biotechs with Blockbuster Potential: Hugh Cleland

By The Life Sciences Report
Published: Today

http://www.gold-speculator.com/life-...+Speculator%29

TLSR: Go to your next idea.

HC: My funds own almost 13% of IntelGenx Corp. (IGXT:OTCQX; IGX:TSX.V). I cannot believe the stock is trading where it's at, considering its achievements in the last 12 months. Its drug Forfivo (bupropion extended-release), for major depressive disorder, has been approved by the U.S. Food and Drug Administration (FDA). Forfivo is now being marketed by IntelGenx's partner Edgemont Pharmaceuticals LLC (private).

In December 2011, a partnership with Par Pharmaceutical Companies Inc. (PRX:NYSE) was announced, and we're expecting a regulatory filing for that drug sometime soon. The name of the drug and the details are confidential for competitive reasons. IntelGenx's CEO has continued to emphasize the size and importance of this project without being specific.

If you look at a research report from Ram Selvaraju, who is head of equity research at Aegis Capital, you'll see he hasn't given this unnamed product any value whatsoever, but he still has a $3 target price on the stock, which is more than a 400% implied return from IntelGenx's current price ($0.60). I'm expecting Ram will raise his target quite significantly after we see the filing for that undisclosed product. It should be a significant catalyst for the stock, as investors see what a large drug we're dealing with.

Then there is the company's thin-film rizatriptan migraine drug. This drug is being developed in partnership with RedHill Biopharma (RDHL:NASDAQ). The FDA accepted the new drug application (NDA) filing for this drug on June 18, and we now have Feb. 3, 2014, specified as the Prescription Drug User Fee Act (PDUFA) date.

Prescription migraine drugs have global sales of over $5B per year. Maxalt, the drug that IntelGenx has ported to a thin film, had sales of well over $600M in 2012, so this is not a small opportunity, although I get the sense that the Par project has significantly more upside.

Somehow, with this great pipeline and all this success, we are talking about a company with a market cap of $30M. A table-pounding buy, in my view.

TLSR: Why have IntelGenx's shares been weak over the past month?

HC: It got hit fairly hard the last few days of May; a small overhang of warrants remains from a financing a few years ago. I expect that will get chewed through shortly, and we'll have that cash on the balance sheet.
Biohero is online now   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Watch: IntelGenx (IGXT) Submits New Drug Application for Anti-Migraine VersaFilm(TM) stockmountie US Penny Stock Picks 5 07-25-2013 05:16 PM
Strong Buy: IGXT (Mcap $31 M) 1x Drug launched + 2x NDA filings in 1Q13 + Profitable in 2013 Biohero US Penny Stock Picks 0 12-30-2012 07:57 PM
Strong Buy: IGXT (Mcap $29 M) 1x Drug launched + 2x NDA filings in 1Q13 + Profitable in 2013 Biohero US Penny Stock Picks 0 12-27-2012 07:34 AM
Strong Buy: Viagra Spray-NDA in 4Q11 (Mcap 5 M)= 10 BAGGER biotechmaster US Penny Stock Picks 2 04-07-2011 12:50 AM
Buy: GenVec’s TNFerade Nears NDA Status (NASDAQ:GNVC) StocksHaven US Stock Picks 4 11-04-2009 08:17 AM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On